Laser Capture Microdissection Instrument Purchase

激光捕获显微切割仪器采购

• 批准号: 7596104
• 负责人: Jennifer Richer-Mouchantat
• 金额: $ 8.59万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7596104
• 关键词: Adhesives; Adipocytes; Advisory Committees; Biopsy Specimen; Blood Vessels; Cancer Biology; Cancer Center; Cancerous; Cells; Developmental Biology; Disease; Disease Progression; Elements; Equipment; Exhibits; Gene Expression; Genes; Growth Factor; Hormones; Immune; Inflammatory; Institution; Invaded; Maintenance; Malignant Neoplasms; Minority; Molecular; Muscle; Operative Surgical Procedures; Organ; Pathology; Pattern; Population; Research; Research Infrastructure; Research Personnel; Resource Sharing; Services; Signal Transduction; System; Technology; Tissues; Training; Update; base; cancer cell; cell type; instrument; instrumentation; interest; internal control; laser capture microdissection; member; public health relevance; stem cell biology; tumor

DESCRIPTION (provided by applicant): The proposed project is to obtain equipment that utilizes the most modern technological advances in order to update our laser capture microdissection (LCM) equipment. LCM is a technology for isolating pure populations of cells from tissue sections. Cells can be collected based on morphologic or immunohistologic features. Most tissues or even tumors are heterogeneous with different cell types locked in morphologic units exhibiting strong adhesive interactions with adjacent cells, connective stroma, blood vessels, glandular and muscle components, adipose cells, and inflammatory or immune cells. In normal or developing organs, specific cells express different genes and undergo changes according to internal control signals, signals from adjacent cells, and external signals such as hormones or growth factors. In disease pathologies, the diseased cells of interest, such as pre- cancerous cells or invading groups of cancer cells, are surrounded by heterogeneous tissue elements. Cell types undergoing similar molecular changes, such as those thought to be most definitive of the disease progression, may constitute a minority of the volume of the tissue biopsy sample. Information from microdissected cells is therefore more likely to represent the true pattern of gene expression of the pure cell subpopulations of interest in their actual tissue context. This technology has been particularly useful in developmental biology and cancer biology, and recently LCM has also proven instrumental in the study of stem cell biology (see project of major user Dennis Roop). We established LCM as a service offered via our Cancer Center Pathology Core Shared Resource Facility in 2004. We describe the research of several key users of the instrument at our institution as well as a broader use by members of our Cancer Center. Dr. Wilbur Franklin will chair the Advisory Committee responsible for productive, efficient and equitable use of the system. Dr. Jennifer Richer will be responsible for the day-to-day operation and maintenance of the equipment and user training. Productive use will be assured because of the infrastructure of the Cancer Center Pathology Core already in place and a talented and productive group of researchers that now utilize the older version of laser capture microdissection instrumentation. PUBLIC HEALTH RELEVANCE: The proposed project is to obtain equipment that represents the most modern technological advances to update our laser capture microdissection (LCM) capabilities. LCM is a technology for isolating pure populations of cells of interest from mixed populations. This technology is not only important for understanding normal developmental biology, but also numerous diseases including cancer.

描述（由申请人提供）：拟议的项目是获得设备，利用最现代的技术进步，以更新我们的激光捕获显微切割（LCM）设备。LCM是一种从组织切片中分离纯细胞群的技术。可以基于形态学或免疫组织学特征收集细胞。大多数组织或甚至肿瘤是异质的，具有锁定在形态单元中的不同细胞类型，表现出与相邻细胞、结缔组织基质、血管、腺体和肌肉成分、脂肪细胞以及炎症或免疫细胞的强粘附相互作用。在正常或发育中的器官中，特定的细胞表达不同的基因，并根据内部控制信号、来自相邻细胞的信号和外部信号（如激素或生长因子）发生变化。在疾病病理学中，感兴趣的患病细胞，例如癌前细胞或侵入的癌细胞群，被异质组织成分包围。经历类似分子变化的细胞类型，例如被认为是疾病进展最确定的细胞类型，可能构成组织活检样品体积的少数。因此，来自显微切割细胞的信息更可能代表感兴趣的纯细胞亚群在其实际组织背景中的基因表达的真实模式。这项技术在发育生物学和癌症生物学中特别有用，最近LCM也被证明有助于干细胞生物学的研究（见主要用户Dennis Roop的项目）。我们于2004年建立了LCM，作为通过癌症中心病理核心共享资源设施提供的一项服务。我们描述了几个关键用户的仪器在我们的机构，以及更广泛的使用我们的癌症中心的成员的研究。威尔伯富兰克林博士将担任咨询委员会主席，负责富有成效、高效率和公平地使用该系统。Jennifer Richer博士将负责设备的日常操作和维护以及用户培训。由于癌症中心病理学核心的基础设施已经到位，并且现在使用旧版本的激光捕获显微切割仪器的一组有才华和富有成效的研究人员，因此可以确保有效使用。公共卫生相关性： 拟议的项目是获得代表最现代技术进步的设备，以更新我们的激光捕获显微切割（LCM）能力。LCM是一种从混合细胞群中分离纯目标细胞群的技术。这项技术不仅对理解正常的发育生物学很重要，而且对包括癌症在内的许多疾病也很重要。